BBIO Q1 2022 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+266.7% YoY

Gross Profit

$346,00020.4% margin

Operating Income

-$174M-10252.5% margin

Net Income

-$196M-11593.7% margin

EPS (Diluted)

$-1.35

QoQ Revenue Growth

-86.9%

Cash Flow

Operating Cash Flow

-$161M

Free Cash Flow

-$161M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$813M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.0B

Cash & Equivalents

$372M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$462,000	+266.7%
Gross Profit	$346,000	$462,000	-25.1%
Operating Income	-$174M	-$168M	-3.7%
Net Income	-$196M	-$163M	-20.4%

Revenue Segments

Product

$1M86%

License

$235,00014%